Yhdysvallat - englanti - NLM (National Library of Medicine)

indicus pharma llc - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg - letrozole tablets (letrozole) are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see clinical studies (14.2, 14.3) ]. letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see clinical studies(14.4, 14.5) ]. letrozole tablets may cause fetal harm when administered to a pregnant woman and the cl

Yhdysvallat - englanti - NLM (National Library of Medicine)

jiangsu hengrui pharmaceuticals co., ltd. - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg - letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [ see clinical studies ( 14.2, 14.3) ]. letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; microcrystalline cellulose; titanium dioxide; macrogol 8000; sodium starch glycollate; maize starch; iron oxide yellow; colloidal anhydrous silica; lactose monohydrate; purified talc - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Israel - englanti - Ministry of Health

bioavenir ltd, israel - letrozole - film coated tablets - letrozole 2.5 mg - letrozole - letrozole - letrozole farmoz tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole farmoz is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - letrozole -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - letrozole -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - letrozole -

Malta - englanti - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

accord healthcare limited - letrozole - film coated tablet - 2.5 milligram - letrozole